ICCC
ImmuCell Corporation
NASDAQ: ICCC · HEALTHCARE · BIOTECHNOLOGY
$9.95
-4.05% today
Updated 2026-11-05
Market cap
$94.18M
P/E ratio
148.14
P/S ratio
3.07x
EPS (TTM)
$0.07
Dividend yield
—
52W range
$5 – $12
Volume
0.0M
ImmuCell Corporation (ICCC) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$9.95
12-Month target
$4.84
2030 Target
—
Intrinsic (DCF)
$17.65
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 2.57%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.